Safety concerns put an end to Roche’s late-stage diabetes trial

Roche's phase III trial for diabetes candidate aleglitazar has been dogged by safety concerns, prompting the Swiss biotech to discontinue investigation of the drug. The AleCardio trial was evaluating the efficacy and safety of aleglitazar in patients with a recent acute coronary syndrome event and type 2 diabetes mellitus, but a review by the Data and Safety Monitoring Board (DSMB) …